HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Health Claim Approval Costs Unaffordable, Economist Says

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.

You may also be interested in...



Supplement Health Claims "Intermediate Category" Created By CFSAN

Dietary supplement manufacturers will be able to market products with health claims supported by indefinite scientific evidence under an interim procedure set forth in the Oct. 6 Federal Register.

Pearson Injunction Against FDA Denied By Federal Judge

A preliminary injunction against FDA requested by the Pearson v. Shalala plaintiffs was denied May 24 by D.C. federal court judge Gladys Kessler. An appeal was filed May 26 by Emord & Associates (Washington, D.C.).

Vitamin E Health Claim Falls Short Of Significant Scientific Agreement - FDA

FDA has determined a health claim relating vitamin E to a reduced risk of heart disease does not meet the "significant scientific agreement" standard. The agency's decision is articulated in a Jan. 11 letter to the Washington, D.C. firm Emord & Associates, which submitted the claim petition on behalf of Julian Whitaker, MD, Durk Pearson, Sandy Shaw and others.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel